149 related articles for article (PubMed ID: 25287483)
21. [HCV entry as a new therapeutic target in chronic hepatitis C].
Dabrowska MM; Panasiuk A; Flisiak R
Pol Merkur Lekarski; 2009 Aug; 27(158):140-3. PubMed ID: 19856882
[TBL] [Abstract][Full Text] [Related]
22. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
[TBL] [Abstract][Full Text] [Related]
23. [Treatment choice of the antiviral agent for the hepatitis C].
Karino Y
Nihon Rinsho; 2015 Dec; 73 Suppl 9():269-73. PubMed ID: 26845943
[No Abstract] [Full Text] [Related]
24. New hepatitis C therapies.
Pawlotsky JM
Semin Liver Dis; 2014 Feb; 34(1):7-8. PubMed ID: 24782253
[No Abstract] [Full Text] [Related]
25. [Host cholesterol biosynthesis as a potential target for anti-hepatitis C virus strategies].
Saito K; Fukasawa M
Seikagaku; 2016 Jun; 88(3):411-5. PubMed ID: 27483962
[No Abstract] [Full Text] [Related]
26. Practical consequences of hepatitis C virus quasispecies for target-specific antivirals.
Fanning LJ
J Infect Dis; 2008 Sep; 198(6):797-9. PubMed ID: 18637751
[No Abstract] [Full Text] [Related]
27. Efficacy of Direct-Acting Antivirals Compared with Older Agents for Hepatitis C.
Ta K; Zehtabchi S
Am Fam Physician; 2017 Jun; 95(11):Online. PubMed ID: 28671433
[No Abstract] [Full Text] [Related]
28. Hepatitis C virus kinetics in chimeric mice during antiviral therapy.
Dahari H; Perelson AS
Hepatology; 2007 Dec; 46(6):2048-9; author reply 2049-50. PubMed ID: 17935224
[No Abstract] [Full Text] [Related]
29. Tailoring antiviral therapy in hepatitis C.
Davis GL
Hepatology; 2006 May; 43(5):909-11. PubMed ID: 16628667
[No Abstract] [Full Text] [Related]
30. Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.
Harrington PR; Deming DJ; Komatsu TE; Naeger LK
Clin Infect Dis; 2015 Aug; 61(4):666-7. PubMed ID: 26002846
[No Abstract] [Full Text] [Related]
31. [Assessment and monitoring of patients with chronic hepatitis C on antiviral therapy--state of the art in 2003].
Simon K; Szymczak A
Pol Arch Med Wewn; 2004 Jul; 112(1):891-8. PubMed ID: 15526854
[No Abstract] [Full Text] [Related]
32. Optimal duration of pre-liver transplantation anti-hepatitis C virus treatment with direct-acting agent sofosbuvir.
Borentain P; Colson P; Darque A; Gérolami R
Liver Int; 2015 Jun; 35(6):1776. PubMed ID: 25619265
[No Abstract] [Full Text] [Related]
33. Transdisciplinary Approach to Managing Hepatitis C Virus Infection in Patients at a Tertiary Care Cancer Center.
Torres HA; Roach LR; Mahale P; Economides MP; Blechacz B; Miller E; Borchardt R; Rashid A; Oo TH; Shukla B; Farida M; Ericsson CD; Granwehr BP; Raad II
J Natl Compr Canc Netw; 2016 Sep; 14(9):1185-8. PubMed ID: 27587628
[No Abstract] [Full Text] [Related]
34. Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection.
Knops E; Heger E; Koenig C; Moebius U; Lübke N; Kaiser R; Di Cristanziano V; Hüsgen L; Kocyigit C; Rupp J; Sierra S
Clin Microbiol Infect; 2018 Apr; 24(4):440-441. PubMed ID: 29104172
[No Abstract] [Full Text] [Related]
35. Hepatitis C virus infection in Taiwan: Past, present, and future.
Kao JH
J Formos Med Assoc; 2016 Feb; 115(2):65-6. PubMed ID: 26228687
[No Abstract] [Full Text] [Related]
36. A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses.
Beard MR; Ffrench R; Gowans EJ; Helbig KJ; Eyre NM; Douglas MM; Grebely J; Ahlenstiel G; Locarnini S; George J; Shackel NA; White PA; Thompson AJ; Drummer HE
Gastroenterology; 2014 Jul; 147(1):e1-4. PubMed ID: 24861641
[No Abstract] [Full Text] [Related]
37. [Research on hepatitis C virus entry inhibitor].
Zeng Wenting ; Lu X; Wang J; Jin X; Zhu J
Bing Du Xue Bao; 2015 Jan; 31(1):97-105. PubMed ID: 25997338
[TBL] [Abstract][Full Text] [Related]
38. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.
Mariño Z; van Bömmel F; Forns X; Berg T
Gut; 2014 Feb; 63(2):207-15. PubMed ID: 24253934
[No Abstract] [Full Text] [Related]
39. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
Herion D; Hoofnagle JH
Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
[No Abstract] [Full Text] [Related]
40. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
